Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France


Cancer drug-induced osteoporosis (Endorsed by Endocrine Connections)

ea0063s10.1 | Cancer drug-induced osteoporosis (Endorsed by Endocrine Connections) | ECE2019

Mechanisms of skeletal metastasis

Rauner Martina

Skeletal lesions are a frequent complication of breast and prostate cancer. At present, 60–80% of patients with breast or prostate cancer develop bone metastases, which frequently result in skeletal-related events, including pathological fractures, pain, and neurological syndromes that require surgery or radiotherapy, and reduce quality of life. Autocrine and paracrine factors modulate various aspects of bone metastasis, including tumor proliferation, epithelial-to-mesenc...

ea0063s10.3 | Cancer drug-induced osteoporosis (Endorsed by Endocrine Connections) | ECE2019

TSH suppressive therapy and bone

Marcocci Claudio

Thyroid hormones stimulates bone turnover. Increased blood levels of thyroid hormones are associated with a negative balance at individual bone remodeling unit and bone loss. It is well know that hyperthyroidism is a common cause of secondary osteoporosis and increased risk of fragility fractures. Mild hyperthyroidism (suppressed TSH and normal free thyroid hormones), as observed in autonomous thyroid nodules or following administration of TSH-suppressive doses of thyroid horm...